A Phase 2 Study of EZN-2208 in Patients With Metastatic Breast Cancer
NCT01036113
·
clinicaltrials.gov ↗
PHASE2
Phase
TERMINATED
Status
160
Enrollment
INDUSTRY
Sponsor class
Stopped
Program suspended and divested
Conditions
Metastatic Breast Cancer
Interventions
DRUG:
EZN-2208
Sponsor
Enzon Pharmaceuticals, Inc.